In 2023, the global intestinal fistula treatment market is anticipated to be worth US$ 26.64 billion. With ongoing advancements in pharmaceuticals and biotechnology, the global demand for intestinal fistula therapy is expected to expand at a CAGR of 5.8% between 2023 and 2033, reaching approximately US$ 46.82 billion by 2033. Factors such as an increasing prevalence of ulcerative colitis and Crohn’s disease, and the increasing awareness of the disease globally are expected to propel the growth of the intestinal fistula treatment market over the forecast period. Hence, various key industry players are focusing on R&D and exploring new potential candidates for the treatment of intestinal fistula.
As per ClinicalTrials.gov., more than 145 clinical studies are active for ulcerative colitis and Crohn’s disease. The majority of the molecules are in phases 3 & 4 of the clinical trials. For instance, Eli Lilly and Company used mirikizumab drug in phase 3 of clinical trials to evaluate the long-term efficacy and safety of mirikizumab in children and adolescents with moderate-to-severe ulcerative colitis or Crohn's disease. This in turn is anticipated to boost the market growth during the forecast period.
Competitive Landscape
Prominent players in the intestinal fistula treatment market are Livealth Bio Pharma, Boehringer Ingelheim International GmbH, Pfizer Inc., Apsolabs, AstraZeneca, Pipelinepharma, Astellas Pharma Inc., Caspian Tamin Pharmaceutical Company, Eli Lilly, GlaxoSmithKline, Bristol-Myers Squibb, Merck & Co. KGaA and Moderna Inc.
Read More@ https://www.futuremarketinsights.com/reports/intestinal-fistula-treatment-market
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the global intestinal fistula treatment market, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033.
Key Segments Covered in the Intestinal Fistula Treatment Industry Analysis
By Drug Class:
- Anticholinergic
- Proton-Pump Inhibitors
- H2 Blockers
- Antidiarrheals
By Route of Administration:
- Oral
- Parenteral
- Rectal
- Transdermal
- Intravenous
By Distribution Channel:
- Hospital Pharmacies
- Clinical Pharmacies
- Drug Stores
- Online Pharmacies
Fistula treatment in Pune Vithai Piles Clinic provides best treatment for fistula.
We are also provides laser treatment for fistula in Pune
Chronic Intestinal Pseudo Obstruction Treatment in India.
Chronic intestinal pseudo-obstruction (CIP) is a rare disorder of gastrointestinal motility where coordinated contractions (peristalsis) in the intestinal tract become altered and inefficient.
When this happens, nutritional requirements cannot be adequately met.
In CIP the intestines react as if there is a true mechanical obstruction or blockage.
However, when tests are performed, no physical evidence of blockage is found.
There is no unique sign or symptom that allows a positive diagnosis of the pseudo-obstruction.
